soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Cardiovascular risk reduction with once-weekly

Early launch trends appear encouraging, with insurance coverage expanding through major pharmacy benefit managers, supporting broader patient access

Switching Medications : Its important to consult with a professional while considering switching between Semaglutide or Tirzepatide

In simple terms, prebiotics are the fuel, probiotics are potential helpers, and butyrate is the beneficial result

8 This red knee cohort is typically only left with short-term palliative treatment options, such as oral non-steroidal anti-inflammatory drugs (NSAIDs) or intra-articular injections of corticosteroids or hyaluronic acid

Reduces oxidative stress and combats signs of aging and certain degenerate illnesses